Effects of Ginkgo bilob a Extract (EGb 761) on Arteriolar Spasm in a Rat Cremaster Muscle Preparation

International Journal of Microcirculation-Clinical and Experimental

Volumn 16, Issue 2, 1996, Pages 98-104

  Stucker O ^a   Pons, C ^a   Duverger, J P ^a   Drieu, K ^b  

^a MONTPELLIER BUSINESS SCHOOL   (France)

^b IPSEN   (France)

Author keywords

Arteriolar spasm; Cremaster muscle; Ginkgo biloba extract (EGb 761); Ginkgolide B; Nitric oxide; Platelet activating factor; Thromboxane

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; DITERPENE; DRUG DERIVATIVE; GINKGO BILOBA EXTRACT 761; GINKGOLIDE; GINKGOLIDE B; LACTONE; PLANT EXTRACT; PROSTAGLANDIN ENDOPEROXIDE; SEROTONIN ANTAGONIST; THROMBIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE A2; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANIMAL; ARTERIOLE; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; GINKGO BILOBA; MALE; RAT; SKELETAL MUSCLE; SPRAGUE DAWLEY RAT; VASCULARIZATION; VASOCONSTRICTION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; ARTERIOLES; DITERPENES; GINKGO BILOBA; GINKGOLIDES; LACTONES; MALE; MUSCLE, SKELETAL; PLANT EXTRACTS; PLATELET ACTIVATING FACTOR; PROSTAGLANDIN ENDOPEROXIDES, SYNTHETIC; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN ANTAGONISTS; THROMBIN; THROMBOXANE A2; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 0030094986     PISSN: 01676865     EISSN: None     Source Type: Journal    
DOI: 10.1159/000179156     Document Type: Article

References (20)

1. DcFeudis FV: Mechanisms and concepts of action of EGb 761: Theoretical considerations: in DcFeudis FV (ed): Ginkgo biloba Extract (EGb 761): Pharmacological Activities and Clinical Applications. Paris. Elsevier. 1991. pp 147-152.
2. Rcuse-Blom S. Drieu K: Effet de l’extrait de Ginkgo biloba sur le spasine artériolaire chez le lapin. Presse Méd 1986;15:1520-1523.
3. Stücker O. Pons C. Duverger JP. d’Arbigny P. Drieu K: Effects of Ginkgo biloba extract (EGb 761) on in vivo induced, white-platclct, arteri-al-thrombus formation: in Giostre F. DeFeudis FV (eds): Advances in Ginkgo biloba Extract Research. Paris. Elsevier. 1994. voi 3: Cardiovascular Effects of Ginkgo biloba Extract (EGb 761), pp 27-30.
4. Guinot P. Caffrcy E. Lambc R. Darragh A: Tanakan inhibits platelel-activaling-factor-in-duced platelet aggregation in healthy male volunteers. Haemostasis 1989:19:219-223.
5. Költringer P. Eber O: Die kollageninduzierte Thrombozytenaggregation unter parenteraler G inkgo-biloba-Th e ra p i e. Wien Med Wo-chenschr 1989:5:92-94.
6. Barancs J, Ilcllegouach A, Le Ilcgarat M, Vios-sat I, Auget M, Chabrier PE, Braquct P: The effects of PAF-acethcr on cardiovascular system and their inhibition by a new highly specific PAF-acether receptor antagonist BN 52021. Pharmacol Res Commun 1986; 18:717-737.
7. Vicaut E. Stücker O: An intact cremaster muscle preparation for in vivo microcirculation studies. MicrovascRes 1990:39:120-122.
8. Baez S: An open cremaster muscle preparation for the study of blood vessels by in vivo microscopy. Microvasc Res 1973;5:384-393.
9. Auguet M. Dclafiotte S. Chabrier PE. Braquet P: Ginkgo biloba extract (EGb 761) and the regulation of vascular tone; in Clostre F. DcFeudis FV (eds): Advances in Ginkgo biloba Extract Research. Paris. Elsevier. 1994, vol 3: Cardiovascular Effects of Ginkgo biloba extract (EGb 761). pp 19-26.
10. Dclafiotte S, Auguet M, DeFeudis FV, Barattes J, Clostre F, Drieu K, Braquct P: Endothelium-dependent relaxation of rabbit isolated aorta produced by carbachol and by Ginkgo biloba extract. Biomed Biochim Acta 1984;43(suppl): 212-216.
11. Auguet M. Dclafiotte S. Hellegouarch A. Clostre F: Bases pharmacologiques de l'impact vasculaire de l'extrait de Ginkgo biloba.Presse Mcd 1986;15:1524-1528.
12. Stücker O. Pons C. Trouvé R. d’Arbigny P. Drieu K: Effects of EGb 761 on platelet aggregation and blood coagulation. J Mol Cell Cardiol 1994:26:1-17.
13. Dillon PK, Ritter AB, Duran WN: Vasoconstrictor effects of platelet-activating factor in the hamster check pouch microcirculation: Dose-response relationships and pathways of action. Circ Res 1988;62:722-731.
14. Le Breton GC, Venton DL, Enke SE, Halushka PV: 13-Azaprostanoic acid: A specific antagonist of the human blood platelet thromboxane/ endopcroxidc receptor. Proc Natl Acad Sei USA 1979;76:4090-4097.
15. Schumacher WA, Heran CL: Effect of thromboxane receptor antagonists on venous thrombosis in rats. J Pharmacol ExpTher 1988:248: 1109-1115.
16. Tesfamariam B: Selective impairment of endothelium-dependent relaxations by prostaglandin endopcroxide. J Hypcrtcns 1994:12:41-47.
17. Latta EK. Packham MA. Gross PL. Rand ML: Enhanced collagen-induced responses of platelets from rabbits with diet-induced hypercholesterolemia arc due to increased sensitivity to TXA;. Arteriosclerosis Thromb 1994:14: 1379-1385.
18. Willerson JT, Eidt JF, McNatt J, YaoSK, Goli-no P, Anderson HV, Buja LM: Role of thromboxane and serotonin as mediators in the development of spontaneous alterations in coronary blood flow and ncointimal proliferation in canine models with chronic coronary artery stc-nosesand endothelial injury. J Am Coll Cardiol 1991;17(suppl): 101B-110B.
19. Koltai MZ: The effects of prostaglandins and the role of their altered synthesis in diabetes mellitus: in Nagano M. Dhalla NS (eds): The Diabetic Heart. New York. Raven Press. 1991. pp 425-437.
20. 2 receptor antagonists: in Rubanyi GM, Vanhoutte PM (eds): Endothelium-Derived Contracting Factors. Basel. Karger, 1990, pp 39-43.